SCOUT-CAP

Objective

To determine the shortest duration of therapy needed to decrease the development of antimicrobial resistance and risk of antimicrobial toxicity.

Hypothesis

Short course (5 day) therapy is superior to standard course (10-day) beta-lactam therapy (amoxicillin, amoxicillin/clavulanate, cefdinir).

Eligible Subjects

Children aged 6 months to 6 years who have experienced early clinical improvement of pneumonia.

Participation Requirements

Participants must be willing to be randomized to usual care or the treatment group who will have 3 site visits (likely be in-home) where the study team will give instruction on medication and obtain vital signs and a physical assessment.

Participant Reimbursement

Benefits for patients and families include reducing adverse drug events experienced when taking antibiotics, potentially preserving the patients’ microbiome, and helping reduce the rate of antibiotic resistance.

Primary Investigator

Jason Newland, MD, MEd, Professor of Pediatrics, Infectious Diseases, and Stephanie A. Fritz, MD, MSCI, Associate Professor of Pediatrics, Infectious Disease Washington University School of Medicine.

Current Status

Complete